China Resources Boya Bio-Pharmaceutical Group300294.SZValuation Analysis

As of Oct 19, 2026, China Resources Boya Bio-Pharmaceutical Group (300294.SZ) trades at a negative P/E (-115.12x, due to a recent net loss), P/B of 0.95x, P/S of 5.50x, and a dividend yield of 1.59%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 21st percentile over the trailing 10Y window (vs. 14th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 5th percentile within its industry and the 7th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.59%, ranking at the 100th percentile over the trailing 20Y window.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. China Resources Boya Bio-Pharmaceutical Group operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.